Curated News
By: NewsRamp Editorial Staff
August 10, 2026
Tonix Q2 Revenue Surges on TONMYA, Pipeline Advances
TLDR
- Tonix Pharmaceuticals' Q2 revenue surged to $13.5 million, with TONMYA sales leading, positioning the company for a competitive edge in fibromyalgia treatment.
- Tonix's Q2 revenue growth stemmed from TONMYA's 12,592 prescriptions, up 100% sequentially, with coverage expanding to 145 million lives by 2027.
- Tonix's TONMYA provides a new treatment option for fibromyalgia patients, with increased access and ongoing research for depression and Lyme disease.
- Tonix's TONMYA is the first new fibromyalgia drug in 15 years, and the company is now testing it for depression and Lyme disease prevention.
Impact - Why it Matters
This news matters because Tonix's strong TONMYA sales and expanded coverage indicate a significant commercial breakthrough for a new fibromyalgia treatment, which could improve outcomes for millions of patients. The company's advancing pipeline in major depressive disorder and Lyme disease prevention also holds potential for addressing major unmet medical needs. For investors, the revenue growth and cash position signal financial stability and growth prospects, making TNXP a stock to watch. For patients and healthcare providers, these developments could lead to new treatment options in the near future.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) reported a strong second-quarter 2026, with net product revenue of approximately $13.5 million, a significant jump from $2 million in the prior-year period. This growth was primarily driven by about $11 million in net sales of TONMYA, its newly approved fibromyalgia treatment. TONMYA saw 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions rising 36% and refills surging 207%. The drug currently has coverage for roughly 136 million lives across commercial, managed Medicare, and Medicaid channels, and this is expected to expand to about 145 million lives when a managed Medicare agreement takes effect on January 1, 2027.
Beyond TONMYA, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review. The company ended the quarter with approximately $176.2 million in cash and cash equivalents, which, along with third-quarter equity proceeds, is expected to fund operations and capital expenditures into early second-quarter 2027.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on CNS and immunology treatments. Its CNS portfolio includes marketed migraine products Zembrace SymTouch and Tosymra, and it is exploring TONMYA's potential in other indications. The company also has pipeline candidates like TNX-2900 for Prader-Willi syndrome and TNX-1500 for kidney transplant rejection prevention. For more details, visit the full press release at https://ibn.fm/6Yytj and the company's newsroom at https://ibn.fm/TNXP.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Q2 Revenue Surges on TONMYA, Pipeline Advances
